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Abstract Babesia bigemina is a protozoan parasite that
causes babesiosis, a disease with a world-wide distribution in
mammals, principally affecting cattle and man. The unveil-
ing of the genome of B. bigemina is a project in active pro-
gress that has already revealed a number of new targets with
potential interest for the design of anti-babesiosis drugs. In
this context, babesipain-1 has been identified as a proteo-
lytically active enzyme whose three-dimensional structure
has not been resolved yet, but which is known to be inhibited
by cysteine proteases inhibitors such as E64, ALLN, leu-
peptin, and vinyl sulfones. In this work, we introduce (1) a
homology model of babesipain-1; (2) a comparison between
babesipain-1 and falcipain-2, a cysteine protease of the
malaria parasite Plasmodium falciparum; (3) in vitro data for
babesipain-1 inhibition by HEDICINs and HECINs, previ-
ously reported as modest inhibitors of falcipain-2; and (4) the
docked binding conformations of HEDICINs and HECINs in
the model of babesipain-1. HEDICINs presented similar
preferred binding conformations for both babesipain-1 and
falcipain-2. However, in vitro bioassay shows that HEDIC-
INs and HECINs are better inhibitors of babesipain-1 than of
falcipain-2, which could be explained by observed differ-
ences between the active pockets of these proteins in silico.
Results presented herein provide a valuable contribution to
future computer-aided molecular design of new babesipain-
1 inhibitors.
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Introduction
Babesiosis is caused by intraerythrocytic protozoan para-
sites of the genus Babesia, which infect a wide range of
domestic and wild animals, and occasionally man [1]. The
major impact occurs in the cattle industry, where bovine
babesiosis has had a huge economic effect [2]. One of the
most important species that causes babesiosis in cattle is
Babesia bigemina, which is distributed wherever
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Rhipicephalus (Boophilus) sp. ticks are encountered,
including North and South America, Southern Europe,
Africa, Asia and Australia [1]. Although babesiosis can be
controlled with vaccination and treated with antiparasitic
drugs, the vaccines might not confer cross protection due to
the existence of different local variants [3, 4]. Also, many
effective anti-babesiosis drugs have been withdrawn from
the market due to health or environmental safety concerns
[5]. Hence, control of babesiosis currently requires more
specific, fast acting, reliable and safer chemotherapeutic
treatments; consequently, the identification and character-
ization of new drug targets for chemotherapy of bovine
babesiosis is considered a pressing priority [6].
The sequencing of the genome of B. bigemina is in active
finishing and the information retrieved so far has provided a
better understanding of the biology of this parasite and has
also unraveled potential targets, such as cysteine proteases,
that may be of utility in prophylactic and therapeutic inter-
ventions [7]. Although the role of cysteine proteases in piro-
plasms is mostly unknown, the importance of these enzymes
in the life cycle of Babesia sp. was demonstrated in inhibition
studies. It was reported that the inhibition of cysteine proteases
reduces in vitro invasion of erythrocytes and growth of
Babesia bovis [8]. Three genes belonging to the C1 family of
cysteine proteases from B. bigemina, BbiCPL1 to BbiCPL3,
were previously identified [9], and found to share many fea-
tures with papain, including: (1) a 20–23 amino acid putative
transmembrane domain, (2) the presence of the ERFNIN and
GNFD pro-sequence motifs typical of cathepsin L-like cys-
teine proteases [10], (3) conservation of catalytic residues, and
(4) six cysteine residues predicted to be involved in disulfide
bond formation in the mature protease sequence [8]. Recently,
BbiCPL1 (or babesipain-1) was cloned and expressed as a
recombinant enzyme which was active against typical peptide
substrates of cysteine proteases, as well as inhibited by E-64,
ALLN, cystatin and leupeptin [6].
Enzymes from the papain family are the most common
proteases in protozoan parasites, and are essential to the
life cycle and pathogenicity of these organisms [11].
Presently, protozoan cysteine proteases are recognized
drug targets, and specific inhibitors are under validation for
chemotherapy of leishmaniasis, malaria, and trypanoso-
miasis [11, 12]. Consequently, it is very likely that cysteine
proteases from Babesia sp. might become relevant targets
for improving the control of bovine babesiosis. Moreover,
babesipain-1 was recently found to be inhibited by arte-
misinin-vinyl sulfone hybrid molecules, which had been
previously reported as inhibitors of Plasmodium falcipa-
rum cysteine proteases, falcipains, and to effectively inhibit
the growth of P. falciparum cultured parasites [13, 14].
This finding paves the way for the rescuing of antimalarial
compounds as potential anti-babesiosis agents, thus turning
falcipain inhibitors as good starting points for the devel-
opment of babesipain-1 inhibitors.
In view of the above, we have evaluated the inhibition of
babesipain-1 by some compounds, known as HECINs 1 and
HEDICINs 2 (Fig. 1), which were previously reported as
micromolar falcipain inhibitors [15]. The interactions of
these compounds with babesipain-1 were studied in silico, in
order to rationalize in vitro data at the molecular level and
guide future design of suitable inhibitors. However, since the
three-dimensional (3D) structure for babesipain-1 is yet
unavailable, enzyme-compound docking studies were pre-
ceded by the establishment of a rational 3D structure for the
enzyme through homology modeling. This technique offers
a rational alternative to predict protein structure based on
sequence similarity among several proteins of the same class.
The model obtained for babesipain-1 was validated with
various structure/geometry verification tools. The docking
studies with the test compounds also provided insight into the
possible binding modes and interactions of ligands with the
enzyme.
Materials and methods
Experimental
Synthesis of compounds 1–2
Compounds 1a–j and 2a–j were prepared as described in
the literature. Analytical and structural information for
Fig. 1 Structures of test
compounds, previously reported
as micromolar inhibitors of
falcipains
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each compound was found to be in perfect agreement with
reported data [15].
Activity assays
The full length babesipain-1 gene was amplified from B.
bigemina genomic DNA by PCR, and cloned in the pGEX-
6P-1 expression vector (GE Healthcare) as previously
described [14]. Constructs were transformed into Esche-
richia coli BL21 cells (GE Healthcare), and liquid cultures
were induced at an absorbance of 1.0 at 600 nm, for 3 h, with
1 mM IPTG. Insoluble inclusion bodies were washed with
urea buffer, and the resulting denatured and reduced GST-
babesipain-1 protein was refolded and later acidified to
promote auto-activation to an active form. Babesipain-1
activity was assayed by a fluorimetric method as previously
described [13, 14]. Briefly, assays were carried out in 200 lL
assay buffer (10 mM PBS, pH 7.4, 5 mM DTT) containing
20 lL of babesipain-1 activated in assay buffer at 50 lg/mL,
and 5 lL of each concentration of the tested inhibitors.
Reactions were initiated by the addition of a fluorogenic
substrate (Z-Leu-Leu-Arg-AMC, Bachem, Germany) and
the activity was monitored (excitation 355 nm; emission
460 nm) for 30 min, at 37 C on a Fluorescence Microplate
Reader (FLUOstar Omega, BMGLABTECH GmbH, Ger-
many). For all assays, saturated substrate concentrations
were used in order to obtain linear fluorescence curves. Stock
solutions of the inhibitors were prepared in DMSO and serial
dilutions were made also in DMSO. Controls were per-
formed using enzyme alone, substrate alone, enzyme with
DMSO and a positive control (trans-epoxysucciny-L-leucyl-
amido(4-guanidino)butane—E64 (Calbiochem, Germany).
The IC50 values were determined using GraphPad PRISM
software by non-linear regression analysis based on the log
of the concentrations of the inhibitors versus the percentage
of activity. All assays were performed in triplicate.
Computational
Homology modeling
The amino acid sequence of babesipain-1 was retrieved
from the universal protein resource (UniProt) database (ID:
C3VEH9) in fasta format [16]. The retrieved sequence
consisted of 458 amino acids, including those from the
prodomain present in papain-like cysteine proteases. As the
interest of this study was to model the mature (functional
state) cysteine protease, the amino acids from the prodo-
main were cleaved off, based on previously reported
information [9]. Therefore, only the mature sequence,
starting from residue Ser242 and having a total length of
217 amino acids, was used for deriving the homology
model. The BLAST program against Protein Data Bank
(PDB), available at National Center for Biotechnology
Information (NCBI), was used to select template structures
for homology modeling of babesipain-1. Among the
homologous sequences, only hits matching the following
criteria were selected: (1) E-value below 10-4; (2) query
coverage [90 % and sequence identity [35 % or query
coverage [85 % and sequence identity [40 %; (3) pdb
structure with a resolution \2.5 A˚; (4) pdb structure
without missing residues in the active site; (5) pdb structure
with bound ligand.
The templates and the target sequences were then
aligned using the PSI-Coffee mode of T-Coffee v.9.03
[17]. The babesipain-1 models were constructed based on
different alignments, single and multiple. For each align-
ment, 100 models were generated using the standard
‘‘automodel’’ routine of Modeller v.9.11 [18]. The resulting
modeled structures were ranked on the basis of an internal
scoring function, and only those with the least internal
scores were identified and used for model validation. In
addition, the root-mean square deviation (RMSD) of the
models was calculated by superimposing each model on
the different template structures; the quality of the con-
sistency between the templates and the babesipain-1 model
was evaluated using ProSA-web [19, 20], during which
energy criteria for the modeled structure were compared
with the potential mean force obtained from a large set of
known protein structures. The backbone conformation of
the modeled structure was calculated by analyzing the phi
(U) and psi (w) torsion angles using PROCHECK, as
determined by Ramachandran plot statistics [21]. The
quality of babesipain-1 models was estimated using the
qualitative model energy analysis (QMEAN) and the pro-
tein quality predictor (ProQ) servers [22, 23].
Docking
The docking studies were performed as previously descri-
bed [24]. Briefly, the proteins were protonated using the
H?? server [25] assuming a pH of 5.5 and a salinity of
0.15 mol/L. The proteins were then minimized with the
AMBER 11 program [26] by 500 steps of steepest descent,
followed by 2,000 steps of conjugate gradient to remove
bad contacts using a generalized-Born solvent model. The
biomolecular force field ff03 [27] was used. Docking was
performed with GOLD [28] version 5.0.1, allowing full
flexibility for the ligand while keeping the protein fixed.
The docking exploration consisted of 500 independent runs
of the docking algorithm with each compound, using the
default genetic algorithm (GA) search parameters and the
GoldScore scoring function. The binding site was defined
as 15 A˚ radius from the catalytic amino acid Cys25 of
babesipain-1 (numbered according to enzyme mature
domain) models.
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Results and discussion
In vitro inhibition studies
Both HEDICINS 1 and HECINS 2 were evaluated in vitro
for inhibition of babesipain-1, using a fluorimetric method
[13, 14], as described under ‘‘Experimental’’. Close
inspection of data obtained (Table 1, columns 3 and 7), and
comparison with the falcipain inhibitory activities reported
in [15] for the same compounds, shows the following:
1. HEDICINS 1 and HECINS 2 present mid-micromolar
activities against babesipain-1 (IC50 = 9.7–35.8 and
IC50 = 9.8–48.3 lM, respectively) which, in general,
are lower than those formerly observed against falci-
pain-2 (IC50 = 23.1 to [50 lM and IC50 = 14.2 to
[50 lM, respectively); noteworthy, the best babesi-
pain-1 inhibitor in each series, 1g (IC50 = 9.7 lM)
and 2d (IC50 = 9.8 lM), were found previously to be
inactive (IC50 [ 50 lM) against falcipain-2 [15];
2. within the complete set of HEDICINS (1), the
cinnamoyl substituent R has a slight effect on babe-
sipain-1 inhibition activity; hence:
• the fact that the two best compounds of the series
are 1 g (R = p-Cl, IC50 = 9.7 lM) and 1j
(R = m-NO2, IC50 = 10.2 lM), and the worst is
1d (R = p-OMe; IC50 = 35.8 lM), suggests that
the inhibition activity is improved by electron-
withdrawing substituents;
• comparison of 1i (IC50 = 18.6 lM) with 1j
(IC50 = 10.2 lM) suggests that the inhibition
activity benefits more from cinnamoyl substituents
at position meta than at position ortho, while the
difference between meta and para positions (1e vs.
1f; IC50 = 29.1 and 28.1 lM, respectively) is
negligible;
3. within the HECINS series (2), the influence of the
cinnamoyl substituent R on babesipain-1 inhibition
resulted as follows:
• in contrast to HEDICINS 1, compounds 2 with
electron-donating R groups seem to be more
interesting inhibitors, as the best one is 2d
(R = p-OMe; IC50 = 9.8 lM), whereas the chlo-
rinated (2g), fluorinated (2e, f) and nitrated (2j)
analogues are the worst (IC50 2g & 2f \ 2e
 2j);
• as for HEDICINS 1, no preference between meta
and para position was observed for the cinnamoyl
substituent R in HECINS 2 (2e vs. 2f; IC50 values
of 20.9 and 17.4 lM, respectively).
4. the influence of both the lipophilicity of the test
compounds (clogP values) [29] and the bulkiness of
their cinnamoyl ring substituents R (Charton’s steric
parameter, m) [30] on inhibition activity was also
assessed, but no clear correlation was found (support-
ing information; Table S1).
Template selection and sequence alignment
Since the accuracy of a homology model is related to the
degree of sequence identity and to the similarity between
template and target, template search and sequence align-
ment are crucial steps in homology modeling. Among the
homologous sequences identified with the BLAST program
against PDB, only those matching the following criteria
were selected as templates: (1) E-value below 10-4; (2)
Table 1 In vitro data on compounds 1a–j and 2a–j for babesipain-1 and falcipain-2 inhibition activity
Cpd R Babesipain-1
IC50 (lM)
FP-2
IC50 (lM)
a
Cpd R Babesipain-1
IC50 (lM)
FP-2
IC50 (lM)
a
1a H 30.8 50 2a H 20.3 [50
1b p-Me 31.3 [50 2b p-Me 13.4 28.5
1c p-iPr 27.7 [50 – – – –
1d p-OMe 35.8 [50 2d p-OMe 9.8 [50
1e m-F 29.1 23.1 2e m-F 20.9 [50
1f p-F 28.1 50.0 2f p-F 17.4 [50
1g p-Cl 9.7 [50 2g p-Cl 17.9 41.3
1h p-Br 11.0 48.3 2h p-Br 14.2 33.1
1i o-NO2 18.6 [50 – – – –
1j m-NO2 10.2 28.1 2j m-NO2 48.3 14.2
E64b – 13.7 24.6 – – 13.7 24.6
a As reported in [15]
b In nM
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query coverage [90 % and sequence identity [35 % or
query coverage [85 % and sequence identity [40 %; (3)
pdb structure with resolution \2.5 A˚; (4) pdb structure
without missing residues in the active site; (5) pdb structure
with bound ligand.
Table 2 shows PDB codes, chain, UniProt accession
numbers, scientific organism that each template sequence
belongs to, sequence identity, query coverage, resolution of
the structures and E-value for all sequences chosen as
templates.
A multiple alignment of the sequences of the template
and of the target is presented in Fig. 2. For simplicity, the
numbering was started at 1 for all the alignments per-
formed. The average sequence homology of babesipain-1
with the six homologs was 41 %, ranging from 38 to 43 %.
Based on their sequences, babesipain-1 and selected tem-
plates are classifiable as cysteine peptidases belonging to
Clan CA, subfamily C1A. This peptidase subfamily utilizes
catalytic glutamine (Gln19), cysteine (Cys25), histidine
(His155) and asparagine (Asn177) residues, always keep-
ing this ordering [31]. These four amino acids are present
in three separate, well conserved regions of the primary
sequence of the mature protease, known as the cysteine,
histidine, and asparagine active site regions of cysteine
proteases (Fig. 2). Alignment of babesipain-1 with the
selected templates showed strict conservation of the cata-
lytic residues, and low polymorphism in their surrounding
areas. Notably, the tryptophan (Trp179) that forms the
‘‘oxyanion hole’’ together with Gln19 is also preserved
[32], and other additional structurally conserved regions
are observed, thus making the selected hits suitable
templates.
Model evaluation
In general, the Modeller code appears to perform best when
using two or three templates compared to a single one [33].
Therefore, homology models were built based on different
alignments, performed with PSI-Coffee mode of T-Coffee,
using a single 3D selected template and all the possible
combinations of two to three selected homolog proteins,
giving a total of 41 different alignments. For each align-
ment, 100 models were obtained using Modeller [18],
totalizing 4,100 models for babesipain-1.
The outputs from Modeller were evaluated using a sta-
tistical evaluation method, Z-DOPE, a normalized atomic
distance-dependent statistical potential based on known
protein structures, where a score of \-1 indicates a
‘‘reliable’’ model (i.e., it indicates that 80 % of its Ca
atoms are within 3.5 A˚ of their correct positions) [34].
Therefore, only those models with a Z-DOPE score equal
to or lower than -1 were taken for further validation
analysis (Table 3). To select the final model of babesipain-
1, among the nine listed models, additional validation tools
were employed, such as PROCHECK, Prosa, ProQ,
QMean, and the following criteria were set: (1) [90 % of
amino acids in the most favorable region as determined by
PROCHECK; (2) Prosa Z-score in accordance with those
obtained for the pdb structures of the templates used to
derive each of the models; (3) a LG score[5 and a MaxSub
[0.5 as determined by ProQ; and (4) a QMEAN score
[0.75 [19–21, 23, 35].
By comparing the different parameters shown in Table 3,
only model 7 (1S4V-2BDZ_51), derived from the multiple
sequence alignment of babesipain-1 with templates 1S4V
and 2BDZ, was found to match the four criteria established.
When compared to the original structures, the alignment
used to obtain this model showed one of the highest PSI-
coffee alignment scores and one of the lowest RMSDs,
which reinforces the good quality of the model. In more
detail, the validation results for model 7 of babesipain-1,
determined by Ramachandran plot statistics (Fig. 3) per-
formed with PROCHECK [21], revealed that 90.9, 7.0, 1.1
and 1.1 % of the residues were located in the most favorable,
additionally allowed, generously allowed and disallowed
regions, respectively. Although this model babesipain-1
presented two amino acids (Arg102, Asp199) in disallowed
regions, they were out of the binding cavity; the Ca of the
closest amino acid, Asp199, was distant from approximately
20 A˚ of Ca of the catalytic Cys25. Moreover, the PRO-
CHECK G-factor value of -0.07 for the final model also
indicated the good quality of the constructed model.
Table 2 Babesipain-1 homologs identified with BLAST according to the established search criteria (see text)
PDB code (chain used) Uniprot code Organism Identity (%) Coverage (%) PDB resolution (A˚) E-value
1EWM (A) P25779 Trypanosoma cruzi 43 91 2.00 1 9 10-41
1S4 V (A) O65039 Ricinus communis 41 87 2.00 2 9 10-43
2BDZ (C) P84346 Jacaratia mexicana 38 95 2.10 4 9 10-43
2OUL (A) Q9N6S8 Plasmodium falciparum 41 94 2.20 1 9 10-46
2P7U (A) Q95PM0 Trypanosoma brucei rhodesiense 43 90 1.65 2 9 10-42
3BWK (B) Q9NAW4 Plasmodium falciparum 41 94 2.42 3 9 10-45
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Model 7 was also evaluated with the ProSA-web program
by examining whether or not the interactions of each residue
with the rest of the protein structure are favorable [19, 20].
The Z-score, provided by ProSA-web from the calculation
of the knowledge-based mean fields, is used to judge the
quality of protein folds, thus indicating the overall quality of
the model. The value of the Z-score is displayed in a plot that
contains the Z-scores of all experimentally determined
protein chains in current PDB. Figure 4 shows the Z-score
plots of 1S4V (A), model 7 of babesipain-1 (B) and 2BDZ
(C), which are -7.98, -6.48 and -6.85, respectively.
Although the Z-score of model 7 is slightly lower than that of
template 1S4V, it is in the same range of template 2BDZ and
it is a perfect fit within the structures in PDB.
ProQ is a neural network based method developed to
predict the quality of protein models by recognizing folds
that are not compatible with a protein sequence [23]. The
quality of the model is quantified by two indices: LG score
(i.e., the -log of a p value) [36] and MaxSub (ranging 0–1)
[37]. Depending on the specific values of these indices, the
model can be qualified as: correct if LG score [1.5 and
MaxSub [0.1, as good if LG score [3 and MaxSub [0.5,
Fig. 2 Multiple sequence
alignment performed with PSI-
Coffee mode of T-Coffee [17]
of the amino acid sequence of
babesipain-1 (bbspn1) and of
the selected templates. The
boxes indicate the cysteine,
histidine and asparagine
catalytic regions, respectively.
The arrows show the catalytic
residues glutamine (Gln19),
cysteine (Cys25), histidine
(His155) and asparagine
(Asn177), with residue
numbering according to the
sequence of mature
babesipain-1
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and as very good if LG score[5 and MaxSub[0.8). Thus,
model 7 of babesipain-1 was evaluated as ‘‘very good’’
according to the LG score (5.384) and ‘‘good’’ according to
the MaxSub index (0.565).
The QMEAN score corresponds to the global score of
the whole model, on the basis of a linear combination of six
structural descriptors, reflecting the predicted model reli-
ability ranging from 0 to 1 with higher scores for reliable
models. Accordingly, the global score of 0.751 reflects the
reliability of the babesipain-1 model. Furthermore, the
quality of the model can be compared to reference struc-
tures of high resolution obtained from X-ray
Table 3 Validation scores from Modeller, PROCHECK, ProQ, ProSA and Qmean for the constructed models
Model Alignment
(PSI-coffee score)
Modeller
(Z-DOPE)
PROCHECK
(%)a
ProQ
LG score
ProQ
MaxSub
ProSA
(Z-score)
Qmean score
(Z-score)b
RMSD
(A˚)c
1 1EWM-1S4V-2BDZ_42
(91)
-1.06 88.7
10.2
1.1
0.0
5.068 0.536 -6.43 0.773
(0.02)
1.14
0.80
0.64
2 1S4V-2BDZ_18
(93)
-1.06 91.4
7.0
0.0
1.6
5.118 0.555 -6.31 0.742
(-0.32)
0.91
0.65
3 1S4V-2BDZ_54
(93)
-1.05 91.4
7.5
0.0
1.1
5.318 0.560 -6.20 0.706
(-0.70)
0.94
0.67
4 1EWM-1S4V-2BDZ_51
(91)
-1.04 87.6
11.3
0.5
0.5
5.091 0.508 -6.58 0.720
(-0.55)
1.11
0.74
0.61
5 1EWM-1S4V-2BDZ_76
(91)
-1.04 89.8
8.1
2.2
0.0
5.358 0.547 -6.25 0.718
(-0.57)
1.15
0.80
0.67
6 2BDZ-2P7U_77
(89)
-1.03 82.3
14.5
1.6
1.6
5.394 0.575 -6.60 0.703
(-0.73)
1.08
0.87
7 1S4V-2BDZ_51
(93)
-1.01 90.8
7.0
1.1
1.1
5.384 0.565 -6.48 0.751
(-0.22)
0.79
0.71
8 1S4V-2P7U_13
(89)
-1.01 88.7
10.2
1.1
0.0
5.391 0.543 -6.39 0.677
(-1.01)
0.82
1.10
9 1S4V-2P7U_68
(89)
-1.00 90.3
8.1
1.6
0.0
5.297 0.538 -6.64 0.684
(-0.93)
0.61
1.10
a Values correspond to the percentages of residues that are located in the most favorable, additionally allowed, generously allowed and
disallowed regions, respectively
b The first value corresponds to the QMEAN global score, while the value between parenthesis refers to the QMEAN Z-score
c RMSD values of bebesipain-1 model compared to the 3D structures of the templates used for the alignment (listed in the same order as column
2)
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crystallography analysis through QMEAN Z-score, where a
value of 0 is the average value for a good model [35].
According to Benkert et al. [35], QMEAN Z-score provides
an estimation of the ‘‘degrees of nativeness’’ of the struc-
tural features observed in a model and indicates if the
model has a quality comparable to experimental structures.
In the present analysis, QMEAN Z-score for babesipain-1
model is -0.22 (Fig. 5) that, together with the other vali-
dation analyses presented above, reinforces the good
quality of the derived model for babesipain-1. The model
coordinates are supplied as Supporting Information.
Babesipain-1 structure
Typical papain-like cysteine protease features were
observed for the modeled structure of babesipain-1,
composed of two domains, an a-helix-rich (L) domain
and a b-sheet-rich (R) domain, separated by a groove
containing the active site (Fig. 6a). The L domain is
composed of four helices and the R domain is formed by
six b-sheets and three small helices at the surface
(Fig. 6a, c), which are typical features of the C1 papain-
like fold [38]. The C- and N-termini of the R and L
domains, respectively, bind to the L and R domains to
stabilize the binding region.
Fig. 3 Ramachandran plot of the homology modeled structure of
babesipain-1. The different colored areas indicate ‘‘disallowed’’
(beige), ‘‘generously allowed’’ (yellow), ‘‘additional allowed’’
(brown), and ‘‘most favored’’ (red) regions
Fig. 4 ProSA analysis for the model structure of babesipain-1 (b) the template structures, 1S4V (a) and 2BDZ (c) with Z-scores values of -6.48,
-7.98 and -6.85, respectively
Fig. 5 Absolute quality of babesipain-1 model as assessed by QMEAN
Z-score. Good models are generally located in the dark zone. The red
marker indicates the positioning of babesipain-1 model 7
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Babesipain-1 contains the seven cysteine residues
common to the papain family, six of them involved in
disulfide bonds (Cys22–Cys63, Cys56–Cys95 and Cys148–
Cys201); the seventh residue, Cys25, is the active catalytic
residue. Residues that constitute the binding pocket sur-
round the catalytic Cys25, located in the L domain at the
N-terminus of helix-1, as shown in Fig. 6a. In the vicinity
of Cys25 is His155, placed at the R domain at the N-ter-
minus of sheet-5, and Asn177, which may facilitate the
appropriate orientation for the formation of the thiolate/
imidazolium ion pair (Fig. 6b). In babesipain-1, as in other
enzymes of the family, Gln19 and Trp179, whose side
chains form the ‘‘oxyanion hole’’, are in a similar orien-
tation (Fig. 6a); this is an important feature for the
enzyme’s proteolytic activity, as the ‘‘oxyanion hole’’
stabilizes the tetrahedral adduct during the nucleophilic
attack of the thiolate anion to the appropriate electron
deficient carbonyl of the substrate [32]. Additionally, we
observed the typical glycine-rich region, comprising
mainly Gly65 and Gly66, that in other papain-like cysteine
proteases was found to provide additional stability to the
complex by forming a constellation of hydrogen bonds
with the substrate [39].
Usually, the active site of papain-like cysteine proteases
is constituted by four pockets [32], S1, S10, S2 and S3, as
shown in Fig. 7. Residues within 6 A˚ of the active site
Cys51 contour the binding pocket and are listed in Table 4.
The S1 pocket is the least defined pocket in cysteine pro-
teases, which comprises Gln19 of the ‘‘oxyanion hole.’’
The most well-defined pocket governing ligand specificity
is the S2 pocket. One of the highly conserved residues in
the S10 pocket is Trp179, the other amino acid that forms
the ‘‘oxyanion hole’’. The glycine-rich region of the
binding site represents the S3 pocket. Although some
Fig. 6 a Modeled structure of babesipain-1, where some conserved
catalytic residues and the disulfide bonds are also represented. The
model contains two typical L (N-terminal) and R (C-terminal)
domains of papain-like cysteine proteases sharing ‘‘V’’ shaped active
site. b The active site residues (Cys25, His155, Asn177) of
babesipain-1. c Predicted secondary structure of babesiapin-1 using
PDBSum server showing two domains of the protein. The N-terminal
domain is dominated by a-helices (red) while the C-terminal domain
is dominated by anti-parallel b-sheets (pink)
Fig. 7 Representation of the babesipain-1 catalytic site surface
showing the S1, S10, S2 and S3 pockets
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differences are observed, the overall topology of the active
site of babesipain-1 is similar to that of other family
members as the majority of the binding site residues are
conserved.
Comparing the sequences of babesipain-1 and falcipain-2,
significant differences are found in the active sites of the
corresponding proteases (Table 4). As previously reported,
these differences are observed mainly in the S2 site [6], while
cavity S1 is more conserved. The nature of the S2 pocket, and
in particular of the residue present in the hollow end of the
pocket, is thought to be essential to the substrate specificity
of clan CA enzymes [32]. Hydrophobic residues usually
constitute the S2 pocket, but the key residue (residue 205 in
papain) present at the bottom of the pocket is not conserved
[32]. In this critical position of falcipain-2 and of babesipain-
1, we find the polar residue Asp234 [40] and the bulky
hydrophobic Phe206 residue, respectively. This difference
was suggested to be responsible for a narrower S2 pocket in
babesipain-1 compared to that in falcipain-2 and, hence,
responsible for the P2 rank ordering observed for babesipain-
1, Val [ Leu [ Phe, in contrast with that in falcipain-2
following Leu [ Phe [ Val ordering [6]. However, the
comparison of babesipain-1 and falcipain-2 structures shows
that the difference in the rank ordering is more likely due to
the presence of the bulky hydrophobic Tyr129 in babesipain-
1, whereas falcipain-2 exhibits the considerably smaller
Ser149. Indeed, we noticed that the S2 pocket in babesipain-
1 is not narrower than that in falcipain-2 in terms of their
heights and widths, but it is definitively shallower due to the
presence of Tyr129 (Fig. 8). Moreover, S2 subsite of babe-
sipain-1 is lined by three bulky hydrophobic residues Phe67,
Tyr129 and Phe206, allowing that small hydrophobic resi-
dues, as valine, are better accommodated than bulky
hydrophobic ones, as phenylalanine, which is in agreement
with the P2 preference rank ordering obtained for babesi-
pain-1. In summary, the above-mentioned analyses indicate
that the model structure is consistent with the current
understanding of the protein structure.
Docking results
Docking calculations were performed to predict the struc-
tures of complexes between babesipain-1 and the two
families of compounds 1 and 2 in order to understand their
inhibitory activities in vitro. While docking algorithms
have been reasonably successful in predicting binding
modes, scoring the poses to predict the binding affinity has
proved to be more challenging. Thus, when accurate cal-
culations of binding energies are required, more precise
methods should be used, such as MM-PBSA. However, as
our main objective was to analyze the interactions estab-
lished between the ligands and the protein, we didn’t
engage into more computationally demanding techniques.
Computational results suggested a preferred binding
mode for HEDICINS, 1, into babesipain-1 binding site by
placing the 7-chloroquinolyl, homo-phenylalanyl, leucyl
and cinnamoyl groups into S20, S10, S1 and S2 subsites,
respectively (Fig. 9a). A similar conformation was previ-
ously obtained when docking the same compounds against
falcipain-2 [15]. However, we noticed that the 7-chloro-
quinoline ring of compounds 1 fails to form p–p interac-
tions with the conserved Trp179 due to steric hindrance by
residue Phe137 in babesipain-1. Instead, in falcipain-2,
close to Trp206 is the small Ala157 residue, which does not
cause such a steric effect, allowing the aforementioned p–p
interactions to occur. We also observed that the first amide
bond following the 7-chloroquinoline ring establishes a
hydrogen bond with the NH of Trp179 side chain. Other
relevant interactions observed between this family of
compounds and babesipain-1 were (1) a hydrogen bond
between the second carbonyl of the ligand and catalytic
His155, and (2) p–p interactions between the aromatic ring
of homo-Phe and Phe137.
The vinyl bond of compounds 1 was placed within
3–5.5 A˚ of the catalytic Cys thiolate. Although 3 A˚ seems to
be a reasonable distance for a covalent bond between the
enzyme and compounds 1, the placement of the rather rigid
cinnamoyl group in S2 severely hinders an attack by the
catalytic Cys, which may account for the modest inhibitory
activity shown by HEDICINS against babesipain-1. Note-
worthy, docking of 1c shows that this compound is able to fit
into the babesipain-1 binding site, which corroborates its
in vitro activity (IC50 = 27.7 lM), but contrasts with the
compound’s behavior as a falcipain-2 inhibitor [15]: 1c was
previously found to be inactive against falcipain-2 due to the
bulky para-isopropyl group blocking its fitting into the
Table 4 Important residues lining the binding pockets of babesipain-1 and falcipain-2
Cysteine protease S10 S1 S2 S3
Babesipain-1 Val130-Phe132-Thr133-
Phe137-His155-Trp179
Gln19-Gly23-
Cys63-Gly64
Phe67-Ser68-Tyr129-
Leu-153-Phe206
Gln59-Ser60-Ser61-
Gly65-Gly66
Falcipain-2 Val150-Val152-Ser153-
Ala157-His174-Trp206
Gln36-Gly40-
Cys80-Asn81
Leu84-Ile85-Ser149-
Leu172-Asp234
Lys76-Asn77-Tyr78-
Gly82-Gly83
The residues are numbered according to enzyme mature domain and those differing in the two enzymes are shown in bold italic
832 J Comput Aided Mol Des (2013) 27:823–835
123
falcipain’s binding site. Hence, it seems that, while shal-
lower, babesipain-1 S2 pocket is wider than its falcipain-2
equivalent, allowing the accommodation of the rigid cin-
namoyl ring presenting a bulky para-isopropyl substituent.
Still, we believe that, although S2 subsite of babesipain-1
can accommodate the cinnamoyl group better than falcipain-
2, a smaller group at this position would be preferable.
Further analyses of the structure of babesipain-1 sug-
gested that a polar group in the para position of the cin-
namoyl ring is not favored, as the hydrophobic side chains of
the residues Phe67, Leu153 and Phe206 are placed at the
bottom of babesipain-1 S2 cavity. This observation is in
agreement with in vitro data, where compound 1d, bearing
the polar p-OMe cinnamoyl substituent, was the worst
inhibitor of the series, with an IC50 value of 35.8 lM.
Nevertheless, the positioning of polar groups at ortho or
meta positions of the cinnamoyl ring is not unfavorable,
because the substituents will be oriented either to the left or
to the right side, being able to establish electrostatic contacts
with the backbone of Gly66 and the backbone of Leu153,
Fig. 8 Amino acids that
constitute the S2 cavity of
babesipain-1 (purple) and
falcipain-2 (pink) are
represented in licorice, ball and
sticks, respectively
Fig. 9 Preferred binding modes of a HEDICINS 1 and b HECINS 2 into babesipain-1 binding site
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respectively. Again, this is in agreement with in vitro results
where compounds 1i and 1j presented better activities (IC50
values of 18.6 and 10.2 lM, respectively) than compound
1d. The higher activity of compound 1j compared to that of
1i is most likely due to the closer proximity of the carbon
prone to suffer the nucleophilic attack. For HEDICINS
bearing a nitro substituent, this happens in the case of the a-
carbon of the a, b-unsaturated carbonyl moiety [15] that, in
the case of compounds 1j and 1i, is at a distance of 3.0 and
4.2 A˚ from the catalytic Cys thiolate, respectively.
By analyzing the docked binding modes of HECINS, 2,
we observed a preference for the positioning of the 7-chlo-
roquinoline group at the S2 cavity, with the cinnamoyl group
pointing toward the catalytic cysteine (Fig. 9b) and placing
the vinyl bond within *4.5 A˚ of this residue. The only
exception to this binding mode was found for compound 2j,
which presents an upside-down orientation with the vinyl
bond located far away from the catalytic site, hence
excluding a possible reaction with the catalytic thiolate
(supporting information, Figure S1). This result is in agree-
ment with in vitro data, where compound 2j
(IC50 = 48.3 lM) was the least active of the HECINS series.
The 7-chloroquinoline ring of the remaining HECINS
establishes several hydrophobic contacts with the hydro-
phobic residues of the S2 subsite. Additionally, the slight
preference observed for cinnamoyl substituents with a higher
electron-donating character could be explained with the
previously reported atomic Fukui indices for HECINS [15],
which were used as a measure of the activation, i.e., electron
density imbalance of the vinyl double bond. Except for 2j,
the b-carbon of the a, b-unsaturated carbonyl moiety, which
is the carbon of the vinyl bond closer to the babesipain-1
catalytic cysteine, was the preferred site of nucleophilic
attack for all HECINS 2. Thus, substituents with a higher
electron-donating character favor electron delocalization
toward the carbonyl group, which will allow a higher acti-
vation of the double bond, and, consequently, favor the
interaction of the b-carbon with catalytic Cys. Again, these
results are in agreement with in vitro data, as the two com-
pounds showing the higher activation of the double bond in
the b-carbon [15], 2b and 2d, were also the best inhibitors of
the series, with IC50 values of 13.4 and 9.8 lM. Finally, as
outlined for HEDICINS 1, although the S2 cavity is wide
enough to accommodate bulky hydrophobic groups, such as
the 7-chloroquine moiety, changing those groups by smaller
ones might favor the inhibitory activity against babesipain-1.
Conclusions
The best babesipain-1 3D model structure was obtained
through homology modeling by combining templates 1S4V
and 2BDZ. The model structure was well validated by
PROCHECK, ProQ, ProSA and QMEAN, and presented
all typical features of papain-like cysteine proteases.
Comparison of falcipain-2 with babesipain-1 demonstrated
that the active cavity of the latter is globally wider, shal-
lower and more hydrophobic. In silico docking studies
showed that all HEDICINS 1 are placed approximately in
the same conformation inside the binding cavity; moreover,
differences between IC50 values of compounds 1 against
babesipain-1 were perfectly explained by stereoelectronic
aspects of the interactions between the distinct ligands and
the enzyme. Similar observations were made in the docking
of HECINS 2 to babesipain-1: all but one of compounds 2
were docked in approximately the same conformation,
where slight differences were in agreement with results
from in vitro experiments; the outlier compound of this
series (2j), whose vinyl bond was farther apart from the
enzyme’s catalytic Cys, was also the worst babesipain-1
inhibitor in vitro. Altogether, these results undeniably
demonstrate the validity of the babesipain-1 3D model
constructed in the present work, which represents a new
doorway toward design and discovery of novel anti-
babesia drugs. Further in vitro studies need to be con-
ducted in order to analyze whether the activity of com-
pounds herein reported against babesipain-1 correlates
with their ability to impair growth of B. bigemina para-
sites. Still, babesipain-1 has similar characteristics to
falcipain-2, and inhibition of the latter is known to
strongly affect normal development of intraerythrocytic
malaria parasites [6, 9, 14]. Therefore, we are strongly
inclined to believe that babesipain-1 will become a rele-
vant therapeutic target against babesiosis.
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